Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 2 institutions in 1 country.
Narcisa MarangociCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. nmarangoci@icmpp.ro.
Daniel TimpuCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. dtimpu@icmpp.ro.
Andreia Corciova"Grigore T. Popa", University of Medicine and Pharmacy, 16 Strada Universitatii, 700115 Iasi, Romania. acorciova@yahoo.com.
Cornelia Mircea"Grigore T. Popa", University of Medicine and Pharmacy, 16 Strada Universitatii, 700115 Iasi, Romania. corneliamircea@yahoo.com.ORCID 0000-0002-1981-8246
Anca-Roxana PetroviciCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. petrovici.anca@icmpp.ro.
Alina NicolescuCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. alina@icmpp.ro.
Elena-Laura UrsuCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. ursu.laura@icmpp.ro.
Valentin NastasaIon Ionescu de la Brad, University of Agricultural Sciences and Veterinary Medicine, 8 Aleea Sadoveanu, 700489 Iasi, Romania. vnastasa67@gmail.com.ORCID 0000-0001-7384-8692
Andra-Cristina BostanaruIon Ionescu de la Brad, University of Agricultural Sciences and Veterinary Medicine, 8 Aleea Sadoveanu, 700489 Iasi, Romania. acbostanaru@gmail.com.ORCID 0000-0003-2209-9630
Mihai MaresIon Ionescu de la Brad, University of Agricultural Sciences and Veterinary Medicine, 8 Aleea Sadoveanu, 700489 Iasi, Romania. mycomedica@gmail.com.ORCID 0000-0002-3103-4954
Mihaela Pertea"Grigore T. Popa", University of Medicine and Pharmacy, 16 Strada Universitatii, 700115 Iasi, Romania. pertea_mihaela@yahoo.com.
Mariana PintealaCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni'' Institute of Macromolecular Chemistry, 41A Aleea Grigore Ghica Voda, 700487 Iasi, Romania. pinteala@icmpp.ro.ORCID 0000-0002-4021-982X
Grigore T. Popa University of Medicine and Pharmacy · RO"Ion Ionescu de la Brad" Iasi University of Life Sciences · RO
Funding
Ministery of Research and Innovation, CNCS - UEFISCDI PN-III-P4-ID-PCCF-2016-0050, within PNCDI III
6 · The paper itself
Abstract
In this study, we proposed formulations of diminazene aceturate (DA) designed to improve its bioavailability and to maximize the therapeutic index in animals by overcoming the rapid degradation under the acidic pH of the stomach. An important consequence is the fact that its amount in the bloodstream is close to the administered dose. This was made possible by incorporating DA into the β-cyclodextrin's (βCD) cavity in a molar ratio of 1:1. The structure of the resulted inclusion complex was established by Raman, DSC, and Wide-Angle X ray Diffraction (WAXD) in solid state and by
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
β-Cyclodextrin as a Functional Excipient Used for Enhancing the Diminazene Aceturate Bioavailability. · full record | OpenQuestion